Revolution Medicines, Inc. (RVMD) Misses Q3 EPS by 20c

Revolution Medicines, Inc. (NASDAQ: RVMD) reported Q3 EPS of ($1.61), $0.20 worse than the analyst estimate of ($1.41). Revenue for the quarter came in at $0 versus the consensus estimate of $1.95 million.

For earnings history and earnings-related data on Revolution Medicines, Inc. (RVMD) click here.

You May Also Be Interested In

• Chewy (CHWY) Reports In-Line Q2 EPS, Offers Guidance
• IMAX Corporation (IMAX) PT Raised to $65 at Rosenblatt
• Belite Bio, Inc, ADR (BLTE) PT Raised to $245 at H.C. Wainwright